pyridoxine has been researched along with ADDH in 14 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metadoxine ER was generally well tolerated, with nausea (17% [10/58] vs 0% [0/59]), fatigue (31% [18/58] vs 27% [16/59]), and headaches (29% [17/58] vs 39% [23/59]) being the most frequently reported adverse effects for the metadoxine ER and placebo groups, respectively." | 2.77 | A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. ( Adler, LA; Aharon-Peretz, J; Ben-Hayun, R; Biederman, J; Daniely, Y; Manor, I; Megiddo, D; Newcorn, JH; Salomy, D; Weizman, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (42.86) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altun, H | 1 |
| Şahin, N | 1 |
| Belge Kurutaş, E | 1 |
| Güngör, O | 1 |
| Manor, I | 3 |
| Newcorn, JH | 2 |
| Faraone, SV | 1 |
| Adler, LA | 3 |
| Dolina, S | 1 |
| Margalit, D | 1 |
| Malitsky, S | 1 |
| Rabinkov, A | 1 |
| Rubin, J | 1 |
| Daniely, Y | 2 |
| Buoli, M | 1 |
| Serati, M | 1 |
| Cahn, W | 1 |
| Ben-Hayun, R | 1 |
| Aharon-Peretz, J | 1 |
| Salomy, D | 1 |
| Weizman, A | 1 |
| Megiddo, D | 1 |
| Biederman, J | 1 |
| Nogovitsina, OR | 1 |
| Levitina, EV | 1 |
| Haslam, RH | 1 |
| Dalby, JT | 1 |
| Rademaker, AW | 1 |
| Nissen, G | 1 |
| Brenner, A | 1 |
| Arnold, LE | 1 |
| Christopher, J | 1 |
| Huestis, RD | 1 |
| Smeltzer, DJ | 1 |
| Magee, R | 1 |
| Maier, D | 1 |
| Reesal, RT | 1 |
| Tikal, K | 1 |
| Vichnar, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder[NCT01243242] | Phase 2 | 120 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder[NCT01685281] | Phase 2 | 36 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The AAQoL scale provides a validated disease-specific measure of the impact of ADHD on quality of life.It is scored as an overall score (29 items) and four subscale scores: life productivity (11 items), psychological health (6 items), life outlook (7 items) and relationships (5 items). Individual items are scored on a five-point Likert-like scale from 'Not at all/Never' (1) to 'Extremely/Very Often' (5). (NCT01243242)
Timeframe: 6 weeks (from visit 1 baseline to visit 6)
| Intervention | units on a scale (Mean) |
|---|---|
| METADOXINE(MG01CI) | 10.93 |
| Placebo | 5.71 |
The primary efficacy endpoint is the difference in change (decrease) in CAARS (Total ADHD Symptoms Score) between the study groups. The CAARS assess the presence and severity of ADHD symptoms and behaviors in adults. Respondents are asked to report their own experiences by rating items pertaining to their behavior/problems using a 4-point Likert-style format ranging from 0 ('Not at all', 'never') to 3 ('Very much', 'very frequently'). The scale measures ADHD symptoms using a 30-item questionnaire.Total score is the sum of all the items ,min=30 Max=90 (NCT01243242)
Timeframe: 6 weeks (from visit 1 baseline to visit 6)
| Intervention | units on a scale (Mean) |
|---|---|
| METADOXINE(MG01CI) | -12 |
| Placebo | -8.93 |
The TOVA is a computerized test that provides information about an individual's sustained attention, speed and consistency of responding, and behavioral self-regulation and executive functioning. ADHD score is a comparison of the subject's response to the CPT test to those of an ADHD group, and is reported as a Z-score. An ADHD score of -1.80 and less fits the profile of the ADHD sample. A score of more than -1.80 (more positive) does not fit the ADHD profile. When comparing ADHD scores the higher the ADHD score the better the performance. (NCT01243242)
Timeframe: 6 weeks( visit 1 baseline to visit 6)
| Intervention | Z score (Mean) |
|---|---|
| METADOXINE(MG01CI) | 4.96 |
| Placebo | 3.01 |
1 review available for pyridoxine and ADDH
| Article | Year |
|---|---|
Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
Topics: Adrenergic alpha-Agonists; Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder wi | 2016 |
5 trials available for pyridoxine and ADDH
| Article | Year |
|---|---|
Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Del | 2013 |
Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2014 |
A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Adult; Age of Onset; Attention Deficit Disorder with Hyperactivity | 2012 |
Effects of megavitamin therapy on children with attention deficit disorders.
Topics: Analysis of Variance; Ascorbic Acid; Attention Deficit Disorder with Hyperactivity; Child; Child, Pr | 1984 |
Megavitamins for minimal brain dysfunction. A placebo-controlled study.
Topics: Ascorbic Acid; Attention Deficit Disorder with Hyperactivity; Child; Female; Glutamates; Humans; Hyp | 1978 |
8 other studies available for pyridoxine and ADDH
| Article | Year |
|---|---|
Homocysteine, Pyridoxine, Folate and Vitamin B12 Levels in Children with Attention Deficit Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Rating Scale; Child; Enzyme-Linked Immunosor | 2018 |
Attention-deficit hyperactivity disorder (ADHD) as a pyridoxine-dependent condition: urinary diagnostic biomarkers.
Topics: Attention Deficit Disorder with Hyperactivity; Biomarkers; Chromatography, High Pressure Liquid; Hum | 2014 |
[Diagnostic value of examination of the magnesium homeostasis in children with attention deficit syndrome with hyperactivity].
Topics: Attention Deficit Disorder with Hyperactivity; Ca(2+) Mg(2+)-ATPase; Calcium; Child; Drug Combinatio | 2005 |
[Psychotropic drugs for children].
Topics: Amitriptyline; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Ce | 1981 |
The effects of megadoses of selected B complex vitamins on children with hyperkinesis: controlled studies with long-term follow-up.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Double-Blind Met | 1982 |
Adult attention deficit hyperactivity disorder and desipramine.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Desipramine; Dysmenorrhea; Family; Female; Hum | 1992 |
[Discussion of the article by M. Vichnar: Experience with the administration of group B vitamins to children with hyperkinetic syndrome].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Pyridoxine; Thiamine | 1989 |
[Experience with the administration of group B vitamins in children with the hyperkinetic syndrome].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Humans; Pyridoxine; Thiamine | 1988 |